ClinicalTrials.gg
CompletedNCT04686591Updated Mar 9, 2021

Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects

A Phase 1 interventional study of AZD9977 capsule 50 mg and [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL) in Cardiovascular Disease, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-09.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Feb 2021, 5 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
30 Years to 60 Years
Sex
Male
01

Study summary

Study to Assess the Absorption, Metabolism, and Excretion of [14C]AZD9977 after a Single-Dose Oral Administration

02

Conditions studied

  • Cardiovascular Disease

Keywords

  • Chronic Heart Failure
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's enrollment of 8 is below the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated, written prior to any study specific procedures.
  2. Healthy male subjects aged 30 to 60 years at the time of signing informed consent with suitable veins for cannulation or repeated venepuncture.
  3. (BMI) of 18.0 to 30.0 kg/m2 (body weight at least 50 kg), as measured at screening.
  4. Must be willing and able to communicate and participate in the whole study.
  5. Must have regular bowel movements (i.e., average stool production of ≥1 and ≤3 stools per day).
  6. Must agree to adhere to the requirements defined in the clinical protocol

Exclusion criteria

Exclusion Criteria:

  1. History of any disease or disorder which, in the opinion of the investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.
  2. History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  3. Clinically significant history of recent depression, seizures or other hyperactive central nervous system condition or ongoing treatment for the same.
  4. History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9977 or the formulation . Hay fever is allowed unless it is active.
  5. Acute diarrhoea or constipation in the 7 days before administration of IMP in the study. If screening occurs >7 days before the first study day, this criterion will be determined on the first study day.
  6. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.
  7. Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis results, as judged by the investigator.
  8. Serum potassium >5.0 mmol/L or fasting blood glucose > (ULN) at screening.
  9. Evidence of renal impairment at screening, as indicated by an estimated of \<80 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation or other evidence of renal impairment.
  10. Subjects with known Gilbert's Syndrome or elevated unconjugated hyperbilirubinaemia or subjects with a history of cholecystectomy or gall stones.
  11. Abnormal resting vital signs (after 5 min rest) of supine systolic BP >140 mmHg and/or diastolic BP >90 mmHg and/or \<50 mmHg and/or HR \<45 or >90 bpm at screening or Period 1 Day 1 pre-dose. Vital signs can be repeated once if abnormal, as judged by the investigator.
  12. Subjects with clinically significant history of recurrent syncope/blackouts or previous history of orthostatic hypotension or those who are noted to have a fall in systolic BP ≥20 mmHg or diastolic BP ≥10 mmHg or elevation in HR of more than 30 bpm when checked between 2 and 5 min after change of posture at screening or at Period 1 Day 1 pre-dose.
  13. Any clinically significant abnormalities on 12-lead , including those which can increase the risk of arrhythmias including >450 msec, as judged by the investigator.
  14. Any positive result on screening for serum surface antigen (HBsAg), antibody (HCV Ab), and (HIV) antibody.
  15. Known or suspected history of drug abuse in the past 2 years, as judged by the investigator.
  16. Has received another new chemical entity (defined as a compound which has not been approved for marketing; including radiolabelled chemical entity) within 90 days of Day 1 in this study. The period of exclusion lasts for 90 days after the final dose or 1 month after the last visit whichever is the longest. Note: subjects consented and screened, but not administered IMP in this study or a previous Phase I study, are not excluded.
  17. Involvement of any AstraZeneca, Quotient Sciences or study site employee or their close relatives.
  18. Subjects who report to have previously received AZD9977.
  19. Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening.
  20. Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 6 months prior to screening. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission.
  21. Positive screen for drugs of abuse at screening or admission to the clinical unit or confirmed positive alcohol breath test at screening or admission to the clinical unit.
  22. Known or suspected history of alcohol abuse or excessive intake of alcohol >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type).
  23. Excessive intake of caffeine-containing drinks or food (e.g., coffee, tea, chocolate) as judged by the investigator. Excessive intake of caffeine defined as the regular consumption of more than 600 mg of caffeine per day (e.g., >5 cups of coffee) or would likely be unable to refrain from the use of caffeine-containing beverages during confinement at the site.
  24. Use of any prescribed or non-prescribed medication including antacids, histamine receptor 2 (H2) antagonists, proton pump inhibitors and analgesics (other than up to 4 g paracetamol/acetaminophen per day), herbal remedies (including but not limited to, St. John's wort, kava, ephedra [ma huang], gingko biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto and ginseng), megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the two weeks prior to the first administration of IMP or longer if the medication has a long half-life. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as determined by the investigator.
  25. Evidence of current SARS-CoV-2 infection.
  26. Subjects with pregnant or lactating partners.
  27. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study.
  28. Subjects who have been administered IMP in an 14C ADME study in the last 12 months.
  29. Subjects who cannot communicate reliably with the investigator.
  30. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
  31. Judgment by the investigator that the volunteer should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
  32. Failure to satisfy the investigator of fitness to participate for any other reason.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    AZD9977

    In Period 1, one 100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capsules) and one 100 µg dose of \[14C\]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL). In Period 2, one 100 mg dose of \[14C\]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq).

    Drug: AZD9977 capsule 50 mg · Drug: [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL) · Drug: [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)

Interventions

  • 100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capusles)

    Also known as: AZD9977

  • Drug[14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)

    One 100 µg dose of \[14C\]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)

    Also known as: [14C]AZD9977

  • Drug[14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)

    One 100 mg dose of \[14C\]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)

    Also known as: [14C]AZD9977

06

What researchers measure

Primary outcomes

  1. Absolute bioavailability of AZD9977

    Absolute bioavailability based on AUC0-inf of oral formulation compared to IV adjusted for dose

    Time frame: Collection of plasma samples from pre-dose until 72 hours post-dose.

  2. The cumulative amount of AZD9977 excreted (CumAe)

    Assessment of the total radioactivity by measuring the cumulative amount of AZD9977 excreted (CumAe)

    Time frame: Collection of urine and faecal samples from pre-dose until 168 hours post-dose.

  3. The cumulative amount of AZD9977 excreted and expressed as a percentage of the administered dose (CumFe)

    Assessment of the rates and routes of elimination by measuring the cumulative amount excreted and expressed as a percentage of the administered dose (CumFe)

    Time frame: Collection of urine and faecal samples from pre-dose until 168 hours post-dose.

  4. Assessment of metabolites in plasma by liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Assessment of metabolites in plasma by liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Time frame: Collection of plasma samples from pre-dose until 72 hours post-dose in period 1 and from pre-dose to 168 hours post-dose in period 2.

  5. Assessment of metabolites in urine by liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Assessment of metabolites in urine by liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Time frame: Collection of urine samples from pre-dose until 72 hours post-dose in period 1 and from pre-dose to 168 hours post-dose in period 2.

  6. Assessment of metabolites in faeces by liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Assessment of metabolites in faeces by liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Time frame: Collection of faecal samples from pre-dose until 168 hours post-dose.

Secondary outcomes

  1. Number of adverse events (AEs) experienced by subjects

    Safety and tolerability assessed through the incidence of AEs

    Time frame: Approximately 8 weeks

  2. Time prior to the first measurable concentration (AZD9977) (tlag)

    Assessment of pharmacokinetics of AZD9977 and \[14C\]AZD9977 and total radioactivity by measuring the time to first measurable concentration (tlag)

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose in period 1 and pre-dose to 168 hours post-dose in period 2.

  3. Time of maximum observed concentration (tmax)

    Assessment of pharmacokinetics of AZD9977 and \[14C\]AZD9977 and total radioactivity by measuring time of maximum observed concentration (tmax)

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose in period 1 and pre-dose to 168 hours post-dose in period 2.

  4. Maximum observed concentration (cmax)

    Assessment of pharmacokinetics of AZD9977 and \[14C\]AZD9977 and total radioactivity by measuring maximum observed concentration (cmax)

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose in period 1 and pre-dose to 168 hours post-dose in period 2.

  5. Area under the curve from time 0 to the time of last measurable concentration (AUC0-t)

    Assessment of pharmacokinetics of AZD9977 and \[14C\]AZD9977 and total radioactivity by measuring area under the curve from time 0 to the time of last measurable concentration (AUC0-t)

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose in period 1 and pre-dose to 168 hours post-dose in period 2.

  6. Area under the curve from time 0 extrapolated to infinity (AUC0-inf)

    Assessment of pharmacokinetics of AZD9977 and \[14C\]AZD9977 by measuring area under the curve from time 0 extrapolated to infinity (AUC0-inf)

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose in period 1 and pre-dose to 168 hours post-dose in period 2.

  7. Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUC%extrap)

    Assessment of pharmacokinetics of AZD9977 and \[14C\]AZD9977 and total radioactivity by measuring area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUC%extrap)

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose in period 1 and pre-dose to 168 hours post-dose in period 2.

  8. Terminal half-life (t1/2)

    Assessment of pharmacokinetics of AZD9977 and \[14C\]AZD9977 and total radioactivity by measuring terminal half-life (t1/2)

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose in period 1 and pre-dose to 168 hours post-dose in period 2.

  9. First order rate constant associated with the terminal (log-linear) portion of the curve (λz)

    Assessment of pharmacokinetics of AZD9977 and \[14C\]AZD9977 and total radioactivity by measuring first order rate constant associated with the terminal (log-linear) portion of the curve (λz)

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose in period 1 and pre-dose to 168 hours post-dose in period 2.

  10. Total body clearance calculated after a single oral administration (AZD9977) (CL/F)

    Assessment of pharmacokinetics of AZD9977 by measuring total body clearance calculated after a single oral administration (AZD9977) (CL/F)

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose in period 1 and pre-dose to 168 hours post-dose in period 2.

  11. Renal clearance calculated using plasma AUC (AZD9977 and [14C]AZD9977) (CLr)

    Assessment of pharmacokinetics of AZD9977 and \[14C\]AZD9977 by measuring Renal clearance calculated using plasma AUC (AZD9977 and \[14C\]AZD9977) (CLr)

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose in period 1 and pre-dose to 168 hours post-dose in period 2.

  12. Apparent volume of distribution based on the terminal phase calculated using AUC0 inf after a single oral administration (AZD9977) (Vz/F)

    Assessment of pharmacokinetics of AZD9977 by measuring apparent volume of distribution based on the terminal phase calculated using AUC0 inf after a single oral administration (AZD9977) (Vz/F)

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose in period 1 and pre-dose to 168 hours post-dose in period 2.

  13. Mean residence time from time 0 to time of the last measurable concentration (AZD9977 and [14C]AZD9977) (MRT0-t)

    Assessment of pharmacokinetics of AZD9977 and \[14C\]AZD9977 by measuring mean residence time from time 0 to time of the last measurable concentration (AZD9977 and \[14C\]AZD9977) (MRT0-t)

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose in period 1 and pre-dose to 168 hours post-dose in period 2.

  14. Mean residence time extrapolated to infinity (AZD9977 and [14C]AZD9977) (MRT0-inf)

    Assessment of pharmacokinetics of AZD9977 and \[14C\]AZD9977 by measuring mean residence time extrapolated to infinity (AZD9977 and \[14C\]AZD9977) (MRT0-inf)

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose in period 1 and pre-dose to 168 hours post-dose in period 2.

  15. Total body clearance calculated after a single intravenous administration ([14C]AZD9977) (CL)

    Assessment of pharmacokinetics of \[14C\]AZD9977 by measuring total body clearance calculated after a single intravenous administration (\[14C\]AZD9977) (CL)

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose

  16. Volume of distribution at steady state after a single intravenous administration ([14C]AZD9977) (Vss)

    Assessment of pharmacokinetics of \[14C\]AZD9977 by measuring volume of distribution at steady state after a single intravenous administration (\[14C\]AZD9977) (Vss)

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose

  17. Volume of distribution based on the terminal phase calculated using AUC0 inf after a single intravenous administration ([14C]AZD9977) (Vz

    Assessment of pharmacokinetics of \[14C\]AZD9977 by measuring volume of distribution based on the terminal phase calculated using AUC0 inf after a single intravenous administration (\[14C\]AZD9977) (Vz)

    Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose

  18. Evaluation of whole blood:plasma concentration ratios for total radioactivity

    Assessment of total radioactivity in whole blood and plasma

    Time frame: Collection of blood samples from pre-dose to 72 hours post-dose in period 1 and pre-dose to 168 hours post-dose in period 2.

07

Study locations

1 site
  • Research Site
    Ruddington, NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. URL:

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Feb 2021, 1 month.

Of 53 industry-sponsored phase 1 interventional studies under Cardiovascular Diseases, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 15. This study's 1 month is below that.

Counting every sponsor, half of 96 studies reached it within 15 months; a quarter within 3 and three quarters within 45.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2020
First posted
Dec 29, 2020
StartActual
Dec 21, 2020
Primary completionActual
Feb 4, 2021
CompletionActual
Feb 4, 2021
Last update
Mar 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04686591
Lead sponsor
AstraZeneca
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
Dec 29, 2020
Start date
Dec 21, 2020
Primary completion
Feb 4, 2021
Completion
Feb 4, 2021
Last update
Mar 9, 2021

Study contacts

Somasekhara Menakuru, MBBS, MS, MRCS, DPM
principal investigator · Quotient Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD9977

Start the discussion